Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $14.52 in the prior trading day, Takeda Pharmaceutical Co ADR (NYSE: TAK) closed at $14.42, down -0.69%. In other words, the price has decreased by -$0.69 from its previous closing price. On the day, 2.1 million shares were traded. TAK stock price reached its highest trading level at $14.44 during the session, while it also had its lowest trading level at $14.385.
Ratios:
Our goal is to gain a better understanding of TAK by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.87 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.40. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 0.65 whereas as Long-Term Debt/Eq ratio is at 0.61.
On March 16, 2023, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $20. Cowen Upgraded its Market Perform to Outperform on July 19, 2022, whereas the target price for the stock was revised from $21 to $24.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 09 ’25 when Thomas Wozniewski bought 6,136 shares for $15.42 per share.
Teresa Marie Bitetti bought 52,649 shares of TAK for $811,848 on Jul 09 ’25. On Jul 09 ’25, another insider, Ramona A Sequeira, who serves as the President, Global Portfolio Di of the company, bought 102,972 shares for $15.42 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TAK now has a Market Capitalization of 47986167808 and an Enterprise Value of 4533366816768. As of this moment, Takeda’s Price-to-Earnings (P/E) ratio for their current fiscal year is 182.99, and their Forward P/E ratio for the next fiscal year is 23.52. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.54 while its Price-to-Book (P/B) ratio in mrq is 0.94. Its current Enterprise Value per Revenue stands at 1.026 whereas that against EBITDA is 3.982.
Stock Price History:
The Beta on a monthly basis for TAK is 0.06, which has changed by 0.04040408 over the last 52 weeks, in comparison to a change of 0.1326145 over the same period for the S&P500. Over the past 52 weeks, TAK has reached a high of $15.69, while it has fallen to a 52-week low of $12.80. The 50-Day Moving Average of the stock is 1.75%, while the 200-Day Moving Average is calculated to be -1.45%.
Shares Statistics:
The stock has traded on average 2.95M shares per day over the past 3-months and 3053430 shares per day over the last 10 days, according to various share statistics. A total of 3.16B shares are outstanding, with a floating share count of 3.16B. Insiders hold about 0.00% of the company’s shares, while institutions hold 2.71% stake in the company. Shares short for TAK as of 1763078400 were 10636685 with a Short Ratio of 3.60, compared to 1760486400 on 9304686. Therefore, it implies a Short% of Shares Outstanding of 10636685 and a Short% of Float of 0.33999999999999997.
Dividends & Splits
In the trailing 12 months, TAK’s forward annual dividend rate was 198.0, compared to 0.32 this year. Against a Trailing Annual Dividend Yield of 13.636363. The stock’s 5-year Average Dividend Yield is 4.64.
Earnings Estimates
Analysts are recommending an EPS of between $73.97 and $73.97 for the fiscal current year, implying an average EPS of $73.97. EPS for the following year is $122.17, with 1.0 analysts recommending between $122.17 and $122.17.
Revenue Estimates
4 analysts predict $1.16T in revenue for . The current quarter. It ranges from a high estimate of $1.17T to a low estimate of $1.13T. As of . The current estimate, Takeda Pharmaceutical Co ADR’s year-ago sales were $1.14TFor the next quarter, 4 analysts are estimating revenue of $1.09T. There is a high estimate of $1.14T for the next quarter, whereas the lowest estimate is $1.04T.
A total of 9 analysts have provided revenue estimates for TAK’s current fiscal year. The highest revenue estimate was $4.54T, while the lowest revenue estimate was $4.45T, resulting in an average revenue estimate of $4.5T. In the same quarter a year ago, actual revenue was $580.36BBased on 16 analysts’ estimates, the company’s revenue will be $4.55T in the next fiscal year. The high estimate is $4.73T and the low estimate is $4.35T.
